These findings support S100A8 and S100A9 as molecular markers of tumor aggressiveness, in keeping with previous studies showing S100A8 and S100A9 overexpression correlating with poor pathological parameters.19, 21 Furthermore, our findings suggest that S1008 and S100A9 may serve as useful clinical targets for anti-metastasis therapy. Here, S100A9 is linked to neoplasm.